# CNTX (Context Therapeutics Inc.) - SEC EDGAR Financial Statements

> Context Therapeutics Inc. reported $36.54M in total assets and a net loss of $43.89M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/CNTX
- Markdown: https://convexityos.com/fundamentals/CNTX.md
- SEC CIK: 0001842952
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:04 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001842952&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$46.08M | Operating profit |
| Net Income | FY 2025 | -$43.89M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.46 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$34.03M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $34.41M | Total debt: $200K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $31.86M | $22.70M | $17.78M | $7.09M | $3.81M | $1.64M |
| **Operating Income** | -$39.70M | -$29.92M | -$25.07M | -$15.38M | -$10.53M | -$2.57M |
| **EBITDA** | -$39.69M | -$29.91M | -$25.06M | -$15.37M | -$10.53M | -- |
| Interest Income | $3.38M | $3.20M | $1.16M | -- | -- | -- |
| Interest Expense | -- | -- | -- | -- | $64K | $661K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$36.12M | -$26.73M | -$23.96M | -$14.84M | -$10.46M | $6.64M |
| Basic EPS | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | $3.07 |
| **Diluted EPS** | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | -$3.96 |
| Basic Shares Outstanding | 95.2M | 58.4M | 16.0M | 16.0M | 2.8M | 348.4K |
| Diluted Shares Outstanding | 95.2M | 58.4M | 16.0M | 16.0M | 2.8M | 2.1M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $5.72M | $12.53M | $7.02M | $11.84M | $8.72M | $7.83M | $3.46M | $2.52M |
| **Operating Income** | -$7.96M | -$14.97M | -$9.34M | -$13.80M | -$10.61M | -$9.76M | -$5.53M | -$4.31M |
| **EBITDA** | -$7.95M | -$14.96M | -$9.34M | -$13.80M | -$10.61M | -$9.75M | -$5.53M | -$4.31M |
| Interest Income | $332K | $419K | $520K | $682K | $834K | $904K | $959K | $964K |
| **Net Income** | -$7.62M | -$14.56M | -$8.68M | -$13.03M | -$9.69M | -$8.83M | -$4.58M | -$3.34M |
| Basic EPS | -$0.08 | -$0.15 | -$0.09 | -- | -$0.10 | -$0.09 | -$0.05 | -- |
| **Diluted EPS** | -$0.08 | -$0.15 | -$0.09 | -- | -$0.10 | -$0.09 | -$0.05 | -- |
| Basic Shares Outstanding | 95.2M | 95.2M | 95.2M | -- | 95.2M | 95.2M | 95.2M | -- |
| Diluted Shares Outstanding | 95.2M | 95.2M | 95.2M | -- | 95.2M | 95.2M | 95.2M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $66.00M | $94.43M | $14.45M | $35.50M | $49.64M | $291K |
| **Cash & Short-Term Investments** | $66.00M | $94.43M | $14.45M | $35.50M | $49.64M | $291K |
| **Total Current Assets** | $68.35M | $97.90M | $16.05M | $37.85M | $51.26M | $299K |
| Property, Plant & Equipment, Net | $30K | $12K | $16K | $28K | $0 | -- |
| Other Non-Current Assets | -- | -- | $0 | $33K | $0 | -- |
| **Total Non-Current Assets** | $140K | $231K | $16K | $112K | $50K | $168K |
| **Total Assets** | $68.49M | $98.13M | $16.06M | $37.97M | $51.31M | $467K |
| Accounts Payable | $2.53M | $1.45M | $2.38M | $936K | $1.83M | $2.71M |
| **Total Current Liabilities** | $8.02M | $2.75M | $4.19M | $3.21M | $3.03M | $9.55M |
| **Total Non-Current Liabilities** | $0 | $112K | $0 | $0 | $0 | $69K |
| **Total Liabilities** | $8.02M | $2.86M | $4.19M | $3.21M | $3.03M | $9.62M |
| **Total Debt (incl. Leases)** | $100K | $200K | -- | $55K | -- | -- |
| Common Stock | $92K | $90K | $16K | $16K | $16K | $332 |
| Retained Earnings | -$130.9M | -$94.78M | -$68.05M | -$44.09M | -$29.25M | -$18.80M |
| **Total Stockholders' Equity** | $60.47M | $95.27M | $11.87M | $34.76M | $48.27M | -$16.92M |
| Total Equity | $60.47M | $95.27M | $11.87M | $34.76M | $48.27M | -$16.92M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $34.41M | $42.99M | $54.53M | $66.00M | $76.94M | $83.52M | $89.35M | $94.43M |
| **Cash & Short-Term Investments** | $34.41M | $42.99M | $54.53M | $66.00M | $76.94M | $83.52M | $89.35M | $94.43M |
| **Total Current Assets** | $36.27M | $45.82M | $58.52M | $68.35M | $79.06M | $86.95M | $92.73M | $97.90M |
| Property, Plant & Equipment, Net | $67K | $74K | $62K | $30K | $34K | $38K | $42K | $12K |
| **Total Non-Current Assets** | $268K | $315K | $342K | $140K | $172K | $204K | $235K | $231K |
| **Total Assets** | $36.54M | $46.13M | $58.86M | $68.49M | $79.23M | $87.15M | $92.97M | $98.13M |
| Accounts Payable | $1.60M | $3.29M | $2.47M | $2.53M | $2.72M | $2.40M | $1.00M | $1.45M |
| **Total Current Liabilities** | $5.50M | $7.88M | $6.53M | $8.02M | $6.04M | $4.56M | $1.90M | $2.75M |
| **Total Non-Current Liabilities** | $31K | $78K | $122K | $0 | $21K | $52K | $83K | $112K |
| **Total Liabilities** | $5.53M | $7.96M | $6.66M | $8.02M | $6.06M | $4.61M | $1.98M | $2.86M |
| **Total Debt (incl. Leases)** | $200K | $200K | $300K | $100K | $100K | $200K | $200K | $200K |
| Common Stock | $92K | $92K | $92K | $92K | $92K | $90K | $90K | $90K |
| Retained Earnings | -$161.8M | -$154.1M | -$139.6M | -$130.9M | -$117.9M | -$108.2M | -$99.36M | -$94.78M |
| **Total Stockholders' Equity** | $31.01M | $38.17M | $52.20M | $60.47M | $73.17M | $82.54M | $90.98M | $95.27M |
| Total Equity | $31.01M | $38.17M | $52.20M | $60.47M | $73.17M | $82.54M | $90.98M | $95.27M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$36.12M | -$26.73M | -$23.96M | -$14.84M | -$10.46M | $6.64M |
| Depreciation & Amortization | $16K | $11K | $12K | $9.3K | $0 | -- |
| Stock-Based Compensation | $1.33M | $842K | $1.08M | $976K | $511K | $219K |
| Change in Payables | $1.10M | -$946K | $1.45M | -$788K | -$866K | $556K |
| **Operating Cash Flow** | -$26.39M | -$14.56M | -$21.05M | -$13.55M | -$8.80M | -$1.03M |
| Capital Expenditure | -$34K | -$7.3K | $0 | -$37K | $0 | -- |
| **Free Cash Flow** | -$26.42M | -$14.56M | -$21.05M | -$13.59M | -$8.80M | -- |
| **Investing Cash Flow** | -$2.03M | -$14.76M | $0 | -$537K | -$250K | $0 |
| Common Stock Issued | $0 | $14.54M | $0 | -- | -- | -- |
| **Financing Cash Flow** | -$15K | $109.3M | $0 | -$102K | $58.39M | $1.15M |
| **Net Change in Cash** | -$28.43M | $79.98M | -$21.05M | -$14.19M | $49.34M | $114K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.62M | -$14.56M | -$8.68M | -$13.03M | -$9.69M | -$8.83M | -$4.58M | -$3.34M |
| Depreciation & Amortization | $7.5K | $6.6K | $4.7K | $4.1K | $4.1K | $4.1K | $4.1K | $2.9K |
| Stock-Based Compensation | $457K | $528K | $409K | $325K | $323K | $389K | $294K | $232K |
| Change in Payables | -$1.69M | $822K | -$67K | -$188K | $325K | $1.39M | -$436K | $408K |
| **Operating Cash Flow** | -$6.58M | -$7.02M | -$11.43M | -$8.94M | -$6.58M | -$5.84M | -$5.03M | -$4.91M |
| Capital Expenditure | $0 | -$18K | -$37K | $0 | $0 | $0 | -$34K | $0 |
| **Free Cash Flow** | -$6.58M | -$7.04M | -$11.47M | -$8.94M | -$6.58M | -$5.84M | -$5.06M | -$4.91M |
| **Investing Cash Flow** | -$2.00M | -$4.52M | -$37K | -$2.00M | $0 | $0 | -$34K | $0 |
| Common Stock Issued | $0 | $0 | $0 | $15K | $0 | $0 | -$15K | -- |
| **Financing Cash Flow** | $0 | $0 | $0 | $0 | $0 | $0 | -$15K | $14.54M |
| **Net Change in Cash** | -$8.58M | -$11.54M | -$11.47M | -$10.94M | -$6.58M | -$5.84M | -$5.08M | $9.63M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -59.7% | -28.1% | -201.9% | -42.7% | -21.7% | -- |
| Return on Assets (ROA) | -52.7% | -27.2% | -149.2% | -39.1% | -20.4% | 1421.8% |
| Current Ratio | 8.52x | 35.62x | 3.83x | 11.80x | 16.90x | 0.03x |
| Quick Ratio | 8.23x | 34.36x | 3.45x | 11.07x | 16.36x | 0.03x |
| Debt to Equity | 0.00x | 0.00x | -- | 0.00x | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -- | -- | -257.4% | -- |
| EPS Growth (YoY) | -- | -- | -- | -- | -220.2% | -- |
| 5Y Net Income / Share Growth | -102.0% | -- | -- | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -141.6% | -120.4% | -77.1% | -59.7% | -36.1% | -41.4% | -30.4% | -28.1% |
| Return on Assets (ROA) | -120.1% | -99.6% | -68.3% | -52.7% | -33.4% | -39.3% | -29.7% | -27.2% |
| Current Ratio | 6.59x | 5.81x | 8.96x | 8.52x | 13.10x | 19.09x | 48.80x | 35.62x |
| Quick Ratio | 6.26x | 5.45x | 8.34x | 8.23x | 12.75x | 18.33x | 47.02x | 34.36x |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
